Amgen (NASDAQ: AMGN) is doing something unusual in 2025. Here's why this $150 billion pharmaceutical powerhouse deserves a ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Zacks Research just turned up the heat on Amgen, raising its FY2025 earnings per share estimate to $20.66 from $20.16. Amgen ...

The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

Agriculture, pharma, electronics, and engineering goods together accounted for over 50 per cent of India's merchandise exports in 2024-25, according to government data, highlighting the country's ...

A federal jury in Delaware has determined that Amgen violated U.S. antitrust laws by engaging in a bundling scheme with pharma middlemen that unfairly advantaged its cholesterol-lowering drug ...